Emerald Advisers LLC Sells 15,622 Shares of Collegium Pharmaceutical, Inc. (NASDAQ:COLL)

Emerald Advisers LLC lessened its holdings in shares of Collegium Pharmaceutical, Inc. (NASDAQ:COLL) by 1.9% in the fourth quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm owned 811,680 shares of the specialty pharmaceutical company’s stock after selling 15,622 shares during the quarter. Emerald Advisers LLC’s holdings in Collegium Pharmaceutical were worth $23,255,000 at the end of the most recent reporting period.

A number of other institutional investors and hedge funds have also recently added to or reduced their stakes in the business. Principal Financial Group Inc. boosted its position in Collegium Pharmaceutical by 3.9% during the third quarter. Principal Financial Group Inc. now owns 1,745,818 shares of the specialty pharmaceutical company’s stock worth $67,459,000 after purchasing an additional 64,958 shares during the period. Geode Capital Management LLC boosted its position in shares of Collegium Pharmaceutical by 0.7% in the third quarter. Geode Capital Management LLC now owns 775,579 shares of the specialty pharmaceutical company’s stock valued at $29,974,000 after acquiring an additional 5,464 shares during the period. Massachusetts Financial Services Co. MA boosted its position in shares of Collegium Pharmaceutical by 17.9% in the third quarter. Massachusetts Financial Services Co. MA now owns 765,692 shares of the specialty pharmaceutical company’s stock valued at $29,586,000 after acquiring an additional 116,327 shares during the period. Charles Schwab Investment Management Inc. boosted its position in shares of Collegium Pharmaceutical by 4.6% in the third quarter. Charles Schwab Investment Management Inc. now owns 381,494 shares of the specialty pharmaceutical company’s stock valued at $14,741,000 after acquiring an additional 16,655 shares during the period. Finally, Royce & Associates LP boosted its position in shares of Collegium Pharmaceutical by 11.0% in the fourth quarter. Royce & Associates LP now owns 339,529 shares of the specialty pharmaceutical company’s stock valued at $9,728,000 after acquiring an additional 33,674 shares during the period.

Collegium Pharmaceutical Trading Up 0.4 %

COLL stock opened at $30.05 on Friday. The company has a market capitalization of $946.15 million, a PE ratio of 12.95 and a beta of 0.99. Collegium Pharmaceutical, Inc. has a one year low of $27.28 and a one year high of $42.29. The company’s 50 day moving average price is $30.69 and its two-hundred day moving average price is $32.67. The company has a debt-to-equity ratio of 3.43, a quick ratio of 0.88 and a current ratio of 0.97.

Collegium Pharmaceutical (NASDAQ:COLL) last posted its quarterly earnings results on Thursday, February 27th. The specialty pharmaceutical company reported $1.63 EPS for the quarter, topping the consensus estimate of $1.54 by $0.09. The firm had revenue of $181.95 million for the quarter, compared to the consensus estimate of $179.68 million. Collegium Pharmaceutical had a net margin of 14.78% and a return on equity of 104.67%. As a group, analysts predict that Collegium Pharmaceutical, Inc. will post 5.62 earnings per share for the current fiscal year.

Insiders Place Their Bets

In other news, CFO Colleen Tupper sold 977 shares of the firm’s stock in a transaction that occurred on Friday, March 14th. The shares were sold at an average price of $30.00, for a total value of $29,310.00. Following the transaction, the chief financial officer now owns 164,269 shares in the company, valued at approximately $4,928,070. This trade represents a 0.59 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, EVP Shirley R. Kuhlmann sold 27,500 shares of the firm’s stock in a transaction that occurred on Friday, January 10th. The stock was sold at an average price of $33.04, for a total transaction of $908,600.00. Following the completion of the transaction, the executive vice president now owns 119,184 shares in the company, valued at $3,937,839.36. This represents a 18.75 % decrease in their position. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 109,193 shares of company stock valued at $3,243,594. 3.98% of the stock is currently owned by corporate insiders.

Analyst Ratings Changes

A number of equities analysts have recently commented on the stock. HC Wainwright restated a “buy” rating and issued a $50.00 price objective on shares of Collegium Pharmaceutical in a research report on Friday, January 10th. Needham & Company LLC raised shares of Collegium Pharmaceutical from a “hold” rating to a “buy” rating and set a $46.00 target price on the stock in a research note on Friday, January 10th. Finally, Piper Sandler lowered their target price on shares of Collegium Pharmaceutical from $37.00 to $36.00 and set a “neutral” rating on the stock in a research note on Tuesday, February 4th. One analyst has rated the stock with a hold rating and five have issued a buy rating to the company. According to data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and a consensus target price of $43.60.

Collegium Pharmaceutical Company Profile

Collegium Pharmaceutical, Inc, a specialty pharmaceutical company, engages in the development and commercialization of medicines for pain management. Its portfolio includes Xtampza ER, an abuse-deterrent, extended-release, and oral formulation of oxycodone for the management of pain severe enough to require daily, around-the-clock, long-term opioid treatment; Nucynta ER and Nucynta IR, which are extended-release and immediate-release formulations of tapentadol, indicated for the management of acute, severe, and persistent pain; Belbuca, a buccal film that contains buprenorphine; and Symproic, an oral formulation of naldemedine for the treatment of opioid-induced constipation in adult patients with chronic non-cancer pain.